MedPath

Effect of Mobile Communication on Congenital Ectopia Lentis Follow-up Adherence

Not Applicable
Active, not recruiting
Conditions
Ectopia Lentis
Interventions
Other: smartphone application service and phone reminder
Registration Number
NCT05628129
Lead Sponsor
Zhongshan Ophthalmic Center, Sun Yat-sen University
Brief Summary

Regular follow-up is essential to successful management of congenital ectopia lentis, but it is often ignored by parents in China.

With rapid economic development, there are increasing numbers of mobile phone users that allow for communication applications to be used in medical care.

The investigators aimed to assess the potential of the smartphone application assisted medical service to increase patient compliance in attendance of follow-up after congenital ectopia lentis treatment.

Detailed Description

Congenital ectopia lentis is a rare ophthalmic disease that seriously harms the physical and mental health of patients. Surgery is the only definite treatment at present. However, severe visual impairment is common in congenital ectopia lentis patients in China, and delayed presentation to hospital and late surgical treatment are found to be the major reasons.

In China, the messaging application WeChat has become the most popular communication tool. As most congenital ectopia lentis patients' parents are younger people, they are more likely to use technology, such as WeChat, in their daily lives. In addition, it allows ophthalmologists to utilize this communication application to relay health related information and reminders to patients. This makes it feasible to apply this smartphone application in improving attendance of follow-up visits.

In this trial, the investigators aimed to assess the potential of the smartphone application assisted medical service to increase patient compliance in attendance of follow-up after congenital ectopia lentis treatment.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
110
Inclusion Criteria
    1. Identified with congenital lens dislocation after surgery and age ≤ 18 years old; 2. Parents were able to access a mobile phone and communicate via the smartphone application (WeChat); 3. Agree to participate in this study and sign the informed consent.
Exclusion Criteria
    1. With Other ophthalmic diseases such as glaucoma, uveitis and corneal disease.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
reminder interventionsmartphone application service and phone reminderOn the basis of standard appointment, parents in intervention group will receive phone reminders at 4 days and 1 day before their scheduled appointments, and relevant scientific and educational knowledge will be relayed to them from the smartphone application at 1 week before appointments.
Primary Outcome Measures
NameTimeMethod
follow-up adherence at 3 months after surgery3 months

the rates of attendance at 3 months (± 3 weeks) after surgery

Secondary Outcome Measures
NameTimeMethod
follow-up adherence at 1 week after surgery1 week

the rates of attendance at 1 week (± 2 days) after surgery

follow-up adherence at 1 month after surgery1 month

the rates of attendance at 1 month (± 1 week) after surgery

best corrected visual acuity3 months

measurement of best corrected visual acuity was carried out using a logarithm of the Minimum Angle of Resolution (logMAR) chart at the baseline and endline visits

replacement rates of glasses3 months

If the difference between the current refraction and the currently worn eyeglass prescription was greater than 2 diopters sphere and/or greater than 1 diopter cylinder, a new prescription was given

amblyopia therapy rate3 months

the rate of amblyopia therapy during 3 months after surgery

referral rate due to systemic diseases3 months

referral rate due to abnormalities in skeletal system and cardiovascular system during 3 months after surgery

CEL knowledge score3 months

change between baseline and endline scores on knowledge about CEL, including six choice questions concerning pathogenesis, symptoms and treatment of CEL

Trial Locations

Locations (1)

Zhongshan Ophthalmic Center, Sun Yat-sen University

🇨🇳

Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath